Crafting BD&L success for a biotech company in the age of AI

How an AI-ready website, public pitch deck, explanatory videos, digital outreach and targeted lead identification supported a biotech company’s business development and licensing campaign.

The challenge: strong science was not translating into partnering visibility

An emerging biotechnology company had a differentiated scientific platform and promising development assets.

However, its public-facing communication did not make the opportunity sufficiently clear to pharmaceutical licensing teams, investors and strategic partners.

The underlying science was complex. Information was distributed across technical presentations, research updates and corporate materials created at different stages of the company’s development. Visitors had to work hard to understand the platform, the lead assets, the supporting evidence and the commercial opportunity.

This created a familiar biotech communication problem: the company knew why its science mattered, but an external reviewer could not reach the same conclusion quickly.

The challenge was not simply to redesign the website or improve the appearance of a pitch deck. The company needed a connected BD&L communication system that could:

• Explain complex science without oversimplifying it

• Communicate with both scientific and commercial audiences

• Protect confidential intellectual property

• Maintain consistency across every public-facing asset

• Improve discoverability through search and AI-assisted research tools

• Identify organizations with a credible strategic reason to engage

  
  

The strategy: build a public-facing BD&L ecosystem

Heylth developed an integrated campaign designed around the way biotech opportunities are discovered, reviewed and shared.

The website, public pitch deck, explanatory videos and outreach materials were treated as parts of one narrative rather than independent deliverables. Each asset answered a different question while reinforcing the same scientific and commercial proposition.

The website established credibility and provided depth. The pitch deck supported rapid evaluation and internal circulation. Videos made the platform and mechanism easier to understand. Digital marketing increased visibility. Lead identification focused outreach on organizations with relevant investment or licensing priorities.

Together, these elements created a clearer pathway from initial discovery to a qualified partnering conversation.

Creating a disclosure-safe scientific narrative

The project began by establishing what the company could communicate publicly.

Scientific claims, development stages, study descriptions, competitive comparisons and pipeline milestones were reviewed for accuracy and consistency.

Public information was separated from material that belonged in a confidential discussion or controlled data room.

The narrative framework defined:

• The unmet medical need

• The company’s technology or therapeutic platform

• The role of each pipeline asset

• The proposed mechanism of action

• Available preclinical or clinical evidence

• Development status and upcoming milestones

• Competitive differentiation

• Intellectual-property positioning at a public level

• The intended investment or partnering opportunity

This framework became the common source for every campaign asset, reducing the risk of contradictory descriptions across the website, deck, videos and outreach materials.

An AI-ready biotech website ensuring BD&L success for a biotech company in the age of AI

The company website was restructured as a scientific and corporate discovery platform.

Visitors could move logically from the unmet need to the technology, pipeline, evidence and development plan. Scientific information remained rigorous, but headings, summaries, diagrams and page architecture made the story easier to navigate for non-specialist decision-makers.

The website was also designed for machine readability. Searchable text, descriptive headings, consistent asset terminology, structured page metadata, accessible image descriptions and clearly labelled development stages helped digital search and AI-assisted research systems interpret the public information more accurately.

The objective was not to manipulate an algorithm or claim guaranteed ranking. It was to ensure that important information was not trapped inside unlabelled graphics, inaccessible animations or image-only documents.

The resulting website could support three audiences simultaneously:

• Scientists looking for biological rationale and supporting evidence

• Pharmaceutical scouts evaluating strategic and pipeline fit

• Investors assessing the team, platform, milestones and opportunity
  

A public non-confidential pitch deck

Heylth created a concise public pitch deck for introductory investor and partnering discussions.

The deck translated the company’s scientific narrative into a sequence that could be reviewed quickly and forwarded internally without requiring an accompanying technical explanation.

Its structure covered the opportunity, scientific platform, pipeline, evidence, differentiation, development pathway and proposed next step. Dense experimental data were converted into readable visualizations while preserving essential information about study models, endpoints, controls and limitations.

The exported presentation retained searchable text and logical labelling so its content could be indexed, extracted and summarized more reliably by document-management and AI-assisted research tools.

Confidential structures, unpublished methods and other protected information were excluded from the public deck and reserved for controlled disclosure after the appropriate agreement.

Explanatory videos for complex science

Short explanatory videos were developed to make the company’s platform and lead programs easier to understand.

Animation, narration, pathway visualization and data storytelling showed how the technology was intended to work and why it could matter within the target disease area. The videos were designed for audiences with different levels of technical familiarity without converting scientific hypotheses into unsupported claims.

The modular format allowed the company to use the videos across its website, investor presentations, partnering outreach, conferences and social channels.

A complex explanation no longer depended entirely on a founder being present to deliver it. The science could begin communicating consistently from the first digital interaction.

Coordinated online marketing

A digital campaign was built around the company’s development narrative and relevant corporate milestones.

Website content, scientific explainers, pipeline updates, videos and leadership perspectives provided substantive reasons to communicate. Rather than relying on repetitive corporate promotion, the campaign connected each update to a meaningful scientific, clinical or strategic development.

Approved content could be distributed through corporate social channels, targeted email communication, industry platforms and conference-related outreach. Each activity directed interested audiences towards the relevant website page, deck or contact pathway.

This created a connected digital footprint through which prospective partners could discover the company, validate its positioning and explore its assets.

Identifying high-fit investors and pharmaceutical partners

Broad lead generation would have produced a large list with limited strategic value. Heylth therefore focused on fit-based identification and prioritization.

Potential pharmaceutical partners were assessed according to factors such as:

• Therapy-area strategy

• Modality and platform interests

• Pipeline gaps

• Preferred development stage

• Geographic priorities

• Relevant licensing and acquisition activity

• Compatibility with the biotech’s partnering objective
  

Potential investors were evaluated according to stage preference, therapeutic focus, investment model, portfolio composition and typical participation in biotechnology financing.

This produced a more focused universe of prospective partners and investors. Each target could then be approached with a message linked to its publicly demonstrated priorities rather than a generic request to review the company.

Preparing content for human and AI-assisted scouting

Pharmaceutical BD teams and investment analysts increasingly use databases, search platforms and AI-assisted tools to find, compare and monitor biotechnology opportunities.

The campaign therefore emphasized structured, consistent and extractable information across the website and public documents. Asset names, modalities, targets, indications, development stages and evidence descriptions were presented consistently so they could be understood by both human reviewers and machine-assisted research workflows.

This did not mean writing for algorithms at the expense of people. It meant removing avoidable barriers to interpretation.

The same scientific proposition could now be:

• Understood by a human reviewer

• Located through relevant searches

• Extracted from public documents

• Compared with competing opportunities

• Circulated internally without losing context

  
  

The impact: a connected route from discovery to discussion

The project transformed fragmented corporate materials into a coordinated BD&L communication system.

It enabled the biotech company to:

• Present a consistent scientific and commercial narrative

• Make its public information easier to discover and interpret

• Explain complex technology through visual storytelling

• Equip leadership with a clear non-confidential pitch deck

• Protect confidential information during early outreach

• Build visibility through coordinated digital communication

• Identify investors and pharmaceutical companies with stronger strategic fit

• Support more relevant and informed introductory conversations

• Prepare public assets for human and AI-assisted research workflows
  

The campaign could not substitute for strong scientific data or guarantee an investment or licensing transaction. Its role was to ensure that a credible opportunity was communicated clearly enough to receive informed consideration.

The broader lesson

Biotech business development does not begin when a confidential data room opens. It begins when an investor, scout or potential partner first encounters the company.

If the website is unclear, the deck is overly academic and the scientific story changes across channels, a promising opportunity can become difficult to evaluate.

An effective BD&L campaign connects scientific strategy, disclosure discipline, visual communication, digital discoverability and targeted partner identification. It gives the right organizations a better opportunity to find the company, understand its assets and decide whether a deeper conversation is warranted.

Preparing your biotech company for investment or licensing outreach?

Heylth develops AI-ready biotech websites, non-confidential pitch decks, scientific videos, digital campaigns and targeted partner-identification programs for emerging life-sciences companies. We offer everything you need for BD&L success for a biotech company in the age of AI

Talk to Heylth about your BD&L communication strategy.

Suggested SEO title: Biotech BD&L Campaign and Investor Readiness Case Study | Heylth

Suggested meta description: See how Heylth combined an AI-ready biotech website, public pitch deck, scientific videos, digital marketing and partner identification into one BD&L campaign.